Nicox’ divestiture of its European commercial operations. Nicox was advised by Michel Dyens & Co.
Michel Dyens & Co was the exclusive Financial Advisor to Nicox for the Transfer of its European commercial operations to a newly-founded company focused on ophthalmic products in Europe (deal value was estimated to circa €26m).
This transaction is a key step in refocusing the Nicox’s resources on its R&D pipeline in ophthalmology including AC‐170 for allergic conjunctivitis, NCX 4251 for blepharitis, NCX 470 for lowering intraocular pressure in patients with glaucoma and ocular hypertension and the new generation of nitric oxide stand‐alone donors in glaucoma. Proceeds of Nicox’ divestiture of its European commercial operations will fund the clinical trials of Nicox’ next generation ophthalmology product candidates